Scripts - even if accurate, will ALWAYS be behind the curve when it comes to tracking $AMRN sales
$AMRN sales are booked on when Vascepa is sold to wholesellers/Distributors - who will be stocking up in 3Q for anticipated approval in September (or earlier).
So irrespective of 2Q figures, 3Q should come in 50% (or more) higher in sales revenue. JMO